GSK forecasts Q1 turnover of £7.58 billion and net profit of £1.74 billion

11 articles · Updated · MarketWatch · Apr 28

The FTSE 100 pharmaceutical giant is set to release first-quarter earnings on Wednesday, with shares up 9.8% year-to-date and new CEO Luke Miels at the helm.
Investors are watching for updates on new drug launches, particularly Blenrep and Exdensur, though meaningful contributions are unlikely due to lack of Medicare reimbursement J-codes.
Analysts are also monitoring the impact of U.S. healthcare spending cuts and any changes to GSK's 2026 financial guidance, following solid 2025 results.

With new drugs stalled by US reimbursement, how will GSK ignite its growth?

Amid US policy shifts, will GSK be forced to slash its 2026 growth forecast?

Is a new $950M acquisition the key to GSK's future respiratory pipeline?

Can China's approval of Blenrep offset the cancer drug's slow start in the US?

As the HIV patent cliff looms, what is GSK's plan for its top franchise?

With the Zantac lawsuit dismissed, where will GSK deploy its newfound capital?